TN2009000427A1 - Use of hdac inhibitors for the treatment of gastrointestinal cancers - Google Patents

Use of hdac inhibitors for the treatment of gastrointestinal cancers

Info

Publication number
TN2009000427A1
TN2009000427A1 TNP2009000427A TN2009000427A TN2009000427A1 TN 2009000427 A1 TN2009000427 A1 TN 2009000427A1 TN P2009000427 A TNP2009000427 A TN P2009000427A TN 2009000427 A TN2009000427 A TN 2009000427A TN 2009000427 A1 TN2009000427 A1 TN 2009000427A1
Authority
TN
Tunisia
Prior art keywords
treatment
gastrointestinal cancers
hdac inhibitors
hdac inhibitor
gastrointestinal
Prior art date
Application number
TNP2009000427A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39683987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000427A1 publication Critical patent/TN2009000427A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TNP2009000427A 2007-05-04 2009-10-16 Use of hdac inhibitors for the treatment of gastrointestinal cancers TN2009000427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91599607P 2007-05-04 2007-05-04
PCT/US2008/062341 WO2008137630A1 (fr) 2007-05-04 2008-05-02 Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux

Publications (1)

Publication Number Publication Date
TN2009000427A1 true TN2009000427A1 (en) 2011-03-31

Family

ID=39683987

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000427A TN2009000427A1 (en) 2007-05-04 2009-10-16 Use of hdac inhibitors for the treatment of gastrointestinal cancers

Country Status (16)

Country Link
EP (1) EP2142190A1 (fr)
JP (1) JP2010526149A (fr)
KR (1) KR20100016171A (fr)
CN (1) CN101674825A (fr)
AU (1) AU2008247603A1 (fr)
BR (1) BRPI0811112A2 (fr)
CA (1) CA2683554A1 (fr)
CL (1) CL2008001269A1 (fr)
IL (1) IL201318A0 (fr)
MA (1) MA31356B1 (fr)
MX (1) MX2009011692A (fr)
RU (1) RU2009144842A (fr)
TN (1) TN2009000427A1 (fr)
TW (1) TW200908964A (fr)
WO (1) WO2008137630A1 (fr)
ZA (1) ZA200906739B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1682538A4 (fr) * 2003-10-27 2009-05-27 S Bio Pte Ltd Hydroxamates lies au biaryle: preparation et applications pharmaceutiques
JP2007509930A (ja) * 2003-10-27 2007-04-19 エス＊バイオ プライベート リミティッド アシル尿素およびスルホニル尿素が結合したヒドロキサマート
WO2006075165A1 (fr) * 2005-01-13 2006-07-20 Btg International Limited Combinaison de virus oncolytiques a des inhibiteurs d'angiogenese

Also Published As

Publication number Publication date
AU2008247603A1 (en) 2008-11-13
EP2142190A1 (fr) 2010-01-13
CL2008001269A1 (es) 2008-12-19
JP2010526149A (ja) 2010-07-29
MX2009011692A (es) 2009-11-10
TW200908964A (en) 2009-03-01
CN101674825A (zh) 2010-03-17
BRPI0811112A2 (pt) 2014-12-23
IL201318A0 (en) 2010-05-31
MA31356B1 (fr) 2010-05-03
KR20100016171A (ko) 2010-02-12
ZA200906739B (en) 2010-06-30
WO2008137630A1 (fr) 2008-11-13
RU2009144842A (ru) 2011-06-10
CA2683554A1 (fr) 2008-11-13

Similar Documents

Publication Publication Date Title
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
TW200833663A (en) Therapeutic agents
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
HK1131608A1 (en) Pyridinone compounds
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MY183014A (en) Compounds for enzyme inhibition
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
TN2011000291A1 (en) Purine compounds
GEP20125599B (en) Proteasome inhibitors
EA201290516A1 (ru) Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a
IN2014MN00139A (fr)
IL193252A0 (en) N-hydroxyacrylamide compounds
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2013012588A (es) Inhibidores de cinasa.
GEP201606513B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
WO2009026446A3 (fr) Inhibiteurs des hdac
EA201170344A1 (ru) Азаиндольные ингибиторы iap
WO2009015368A3 (fr) Inhibiteurs multikinase à utiliser dans le traitement du cancer
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
WO2009019708A3 (fr) Compositions pharmaceutiques et procédés pour le traitement du cancer
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
WO2010075287A3 (fr) Composés et procédés pour le traitement de la douleur et d'autres maladies
TW200719903A (en) Compositions for the treatment of neoplasms